A publicly traded firm before becoming SBIR involved, in October 1999, Centocor was merged into Johnson & Johnson with the firm assuming wholly owned subsidiary status and renamed Janssen Biotech and ceased trading. It is interesting that the firm, renamed Centocor Biologics was sold by J&J in November 2010. Centocor makes therapeutic and diagnostic drugs for cancer, cardiovascular problems, and other diseases. Centocor's products, developed primarily through monoclonal antibody technology, help physicians deliver innovative treatments to improve human health and restore patients' quality of life. When J&J acquired Egea Biosciences in 2004, it was in fact an acquisition by and for Centocor.
